A monoclonal antibody targeting the Wnt receptor was tested in a preclinical investigation of diabetic retinopathy and demonstrated decreased VEGF levels and reduced expression of the adhesion molecules that mediate leukostasis and inflammation (63). Here, VEGFA is linked to diabetic retinopathy.